Bladder Cancer Clinical Trial
A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial Carcinoma of the Bladder
Summary
The main purpose of this study is to identify important treatment attributes for post-radical cystectomy (RC) treatment for participants with MIBC (Muscle-Invasive Bladder Cancer) and assess the relative importance of treatment attributes for post-RC treatment in Japan.
Eligibility Criteria
Inclusion Criteria:
Must reside in Japan and able to speak/read Japanese for the interview/survey
Must have a clinical diagnosis of Muscle-invasive bladder cancer (MIBC):
ypT2-ypT4a or ypN+ MIBC, with prior neoadjuvant cisplatin chemotherapy and underwent radical cystectomy
pT3-pT4a or pN+ MIBC, without prior neoadjuvant cisplatin chemotherapy and underwent radical cystectomy
Must not have received any treatment related to MIBC after radical cystectomy
Exclusion Criteria:
Determined by the physician as being unsuitable for the study (e.g. having any clinically significant psychiatric disorder, cognitive impairment, or having difficulty with communicating in Japanese)
Confirmed diagnosis of other primary cancers at the time of obtaining consent
Current participation in a MIBC clinical trial
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Morrisville North Carolina, 27560, United States More Info
Contact
How clear is this clinincal trial information?